NASDAQ:PMVP PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis $1.11 +0.02 (+1.83%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.12 +0.01 (+0.63%) As of 06/12/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PMV Pharmaceuticals Stock (NASDAQ:PMVP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PMV Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.07▼$1.1250-Day Range$1.05▼$1.4852-Week Range$0.96▼$1.88Volume120,524 shsAverage Volume290,074 shsMarket Capitalization$59.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. Read More PMV Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScorePMVP MarketRank™: PMV Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 621st out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingPMV Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialPMV Pharmaceuticals has a consensus price target of $5.00, representing about 350.5% upside from its current price of $1.11.Amount of Analyst CoveragePMV Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about PMV Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PMV Pharmaceuticals are expected to grow in the coming year, from ($1.45) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PMV Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMV Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMV Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about PMV Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.61% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 10.48, which indicates bearish sentiment.Change versus previous monthShort interest in PMV Pharmaceuticals has recently increased by 5.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPMV Pharmaceuticals does not currently pay a dividend.Dividend GrowthPMV Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.5 / 5News SentimentN/A News SentimentPMV Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for PMV Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders7.57% of the stock of PMV Pharmaceuticals is held by insiders.Percentage Held by Institutions90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PMV Pharmaceuticals' insider trading history. Receive PMVP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMVP Stock News HeadlinesPMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84April 28, 2026 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | finanznachrichten.deTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 13 at 1:00 AM | Reagan Gold Group (Ad)PMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | globenewswire.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?April 20, 2026 | finance.yahoo.comPMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsMarch 6, 2026 | globenewswire.comNew England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid TumorsFebruary 27, 2026 | finance.yahoo.comPMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)November 12, 2025 | msn.comSee More Headlines PMVP Stock Analysis - Frequently Asked Questions How have PMVP shares performed this year? PMV Pharmaceuticals' stock was trading at $1.25 at the beginning of the year. Since then, PMVP stock has decreased by 11.2% and is now trading at $1.11. How were PMV Pharmaceuticals' earnings last quarter? PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) posted its earnings results on Tuesday, May, 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.07. When did PMV Pharmaceuticals IPO? PMV Pharmaceuticals (PMVP) raised $200 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO. Who are PMV Pharmaceuticals' major shareholders? PMV Pharmaceuticals' top institutional investors include BML Capital Management LLC (9.98%), Eversept Partners LP (4.40%), Assenagon Asset Management S.A. (0.68%) and ADAR1 Capital Management LLC (0.43%). Insiders that own company stock include Orbimed Advisors Llc, David Henry Mack, Robert Ticktin, Deepika Jalota and Michael Carulli. View institutional ownership trends. How do I buy shares of PMV Pharmaceuticals? Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PMV Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO), Clean Energy Fuels (CLNE) and Intel (INTC). Company Calendar Last Earnings5/12/2026Today6/13/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 2 weeks, PMVP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMVP CIK1699382 Webwww.pmvpharma.com Phone609-642-6670FaxN/AEmployees50Year Founded2013Price Target and Rating Average Price Target for PMV Pharmaceuticals$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+350.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.98% Return on Assets-62.70% Debt Debt-to-Equity RatioN/A Current Ratio11.14 Quick Ratio11.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.97 per share Price / Book0.56Miscellaneous Outstanding Shares53,330,000Free Float49,295,000Market Cap$59.20 million OptionableOptionable Beta1.36 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:PMVP) was last updated on 6/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
